Your institution may have access to this item. Find your institution then sign in to continue.
Title
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Authors
Pi-Sunyer, F Xavier; Aronne, Louis J; Heshmati, Hassan M; Devin, Jeanne; Rosenstock, Julio; RIO-North America Study Group
Abstract
Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese.